Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab in a Real Life Setting: an Observational rEtrospective Study

NCT04272463 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04272463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab in a Real Life Setting: an Observational rEtrospective Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 13, 2020
Completion date
July 15, 2020
Enrollment
217 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma